ANGO May 2024 7.500 put
| Previous close | 1.6700 |
| Open | 1.6700 |
| Bid | 0.0000 |
| Ask | 2.0500 |
| Strike | 7.50 |
| Expiry date | 2024-05-17 |
| Day's range | 1.6700 - 1.6700 |
| Contract range | N/A |
| Volume | |
| Open interest | 6 |
Business WireAngioDynamics’ APEX-AV Trial Results Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism Presented at SCAI 2024 Scientific Sessions
LATHAM, N.Y., May 06, 2024--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that results from the Acute Pulmonary Embolism Extraction Trial with the AlphaVac System (APEX-AV) were presented at The Society for Cardiovascular Angiography & Interventions (SCAI) 2024 Scientific Sessions hosted in L
Simply Wall St.Insider Spends US$67k Buying More Shares In AngioDynamics
Even if it's not a huge purchase, we think it was good to see that James Clemmer, the CEO, President & Director of...
Insider MonkeyAngioDynamics, Inc. (NASDAQ:ANGO) Q3 2024 Earnings Call Transcript
AngioDynamics, Inc. (NASDAQ:ANGO) Q3 2024 Earnings Call Transcript April 4, 2024 AngioDynamics, Inc. misses on earnings expectations. Reported EPS is $-0.16 EPS, expectations were $-0.14. AngioDynamics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning and welcome to […]
